E

ECO Animal Health Group PLC
LSE:EAH

Watchlist Manager
ECO Animal Health Group PLC
LSE:EAH
Watchlist
Price: 110 GBX 1.38% Market Closed
Market Cap: 74.5m GBX
Section:
 

Relative Value

The Relative Value of one EAH stock under the Base Case scenario is hidden GBX. Compared to the current market price of 110 GBX, ECO Animal Health Group PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EAH Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

0.9
P/S
P/S
Price to Sales
0.9
vs History
49
vs Industry
83
Median 3Y
0.8
Median 5Y
0.9
Industry
2.6
Forward
0.9
More Details
24.7
P/E
P/E
Price to Earnings
24.7
vs History
71
vs Industry
6
Median 3Y
66.4
Median 5Y
32.2
Industry
21.7
Forward
33.4
More Details
8.4
P/OCF
P/OCF
Price to OCF
8.4
vs History
36
vs Industry
43
Median 3Y
4.8
Median 5Y
6.3
Industry
16.6
More Details
26.1
P/FCFE
P/FCFE
Price to FCFE
26.1
vs History
7
vs Industry
33
Median 3Y
8.1
Median 5Y
9.2
Industry
22.5
More Details
0.9
P/B
P/B
Price to Book Value
0.9
vs History
57
vs Industry
75
Median 3Y
0.8
Median 5Y
0.9
Industry
2.3
More Details
0.7
EV/S
EV/S
Enterprise Value to Sales
0.7
vs History
47
vs Industry
90
Median 3Y
0.6
Median 5Y
0.7
Industry
2.9
Forward
0.7
More Details
1.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.4
vs History
63
vs Industry
86
Median 3Y
1.4
Median 5Y
1.5
Industry
5.5
More Details
6.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.3
vs History
69
vs Industry
48
Median 3Y
7.1
Median 5Y
9
Industry
13.1
Forward
7.2
More Details
8.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.9
vs History
76
vs Industry
41
Median 3Y
12.9
Median 5Y
12.9
Industry
16.6
Forward
12.2
More Details
6.8
EV/OCF
EV/OCF
Enterprise Value to OCF
6.8
vs History
31
vs Industry
50
Median 3Y
3.5
Median 5Y
4.7
Industry
15.8
More Details
15.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.9
vs History
28
vs Industry
16
Median 3Y
5.6
Median 5Y
8.1
Industry
19.1
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
49
vs Industry
82
Median 3Y
0.6
Median 5Y
0.7
Industry
1.9
More Details

Multiples Across Competitors

EAH Competitors Multiples
ECO Animal Health Group PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
ECO Animal Health Group PLC
LSE:EAH
74.5m GBP 0.9 24.7 6.3 8.9
US
Eli Lilly and Co
NYSE:LLY
934.9B USD 15.7 50.8 34.1 36.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
484.1B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
251.1B CHF 4.1 26.6 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.8 29.9 108.2 158.4
CH
Novartis AG
SIX:NOVN
205B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
241.5B USD 3.8 12.7 9.1 10.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.8 9 10.4
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
145.1B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
UK
E
ECO Animal Health Group PLC
LSE:EAH
Average P/E: 23.2
24.7
24%
1
US
Eli Lilly and Co
NYSE:LLY
50.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.6
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
E
ECO Animal Health Group PLC
LSE:EAH
Average EV/EBITDA: 398.2
6.3
14%
0.4
US
Eli Lilly and Co
NYSE:LLY
34.1
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
E
ECO Animal Health Group PLC
LSE:EAH
Average EV/EBIT: 1 708.3
8.9
23%
0.4
US
Eli Lilly and Co
NYSE:LLY
36.6
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
1%
10.4
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3

See Also

Summary
EAH intrinsic value, competitors valuation, and company profile.
DCF Valuation
EAH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EAH stock valuation using valuation multiples.
Wall Street Estimates
EAH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EAH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.